Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.54 |
| ▸ | JAK1 | P23458 | 4/20 | 0.54 |
| ▸ | TYK2 | P29597 | 4/20 | 0.54 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.41 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 11/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27280799 | 1.00 | JAK2 (0.54) | JAK2JAK1TYK2JAK3TBK1 | |
| SCHEMBL30726670 | 1.00 | JAK2 (0.54) | JAK2JAK1TYK2JAK3TBK1 | |
| SCHEMBL27280792 | 1.00 | JAK2 (0.54) | JAK2JAK1TYK2JAK3TBK1 | |
| SCHEMBL27280802 | 0.89 | AURKA (0.43) | JAK2JAK1TYK2JAK3TBK1 | |
| SCHEMBL30726574 | 0.85 | KIT (0.51) | JAK2JAK1TYK2JAK3KIT | |
| SCHEMBL27281825 | 0.85 | KIT (0.51) | JAK2JAK1TYK2JAK3KIT | |
| SCHEMBL30726675 | 0.85 | KIT (0.51) | JAK2JAK1TYK2JAK3KIT | |
| SCHEMBL27281827 | 0.85 | KIT (0.51) | JAK2JAK1TYK2JAK3KIT | |
| SCHEMBL30726646 | 0.85 | KIT (0.51) | JAK2JAK1TYK2JAK3KIT | |
| SCHEMBL30726618 | 0.83 | KIT (0.43) | JAK2JAK1TYK2JAK3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387400-A1 | TYK2 INHIBITORS | BIOGEN MA INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4547674-A1 | TYK2 INHIBITORS | Biogen MA Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119731186-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024006493-A1 | TYK2 INHIBITORS | BIOGEN MA INC. (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387400-A1 | TYK2 INHIBITORS | TYK2, CSNK2A3, CSNK2A1 | JAK2 12/4885JAK1 8/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.